MYGN — Myriad Genetics, Inc.
MYGN dilution and offerings
- Active shelf: S-3 (Feb 2026)
- Float: 92.1M shares
$5.85-7.87%
Last close: · regular session
After-hours $5.88 +0.53% ·
Last 60 sessions
Active shelf registration (S-3, Feb 2026). Float: 92.1M shares. Latest SEC filing: 4 on Nov 3, 2026. MYGN closed at $5.85 (-7.87%) on Nov 2, 2026.
Opening the full analysis uses 1 of your 3 free tickers today.
Chart, dilution, float and news for MYGN in the TickerWise workspace.
Company profile
- Sector: Healthcare
- Industry: Medical - Diagnostics & Research
- Country: US
- Exchange: NASDAQ
- Employees: 2,700
- Website: https://myriad.com
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Latest SEC filings for MYGN
Latest MYGN news
- Myriad to sell prenatal health testing business to Labcorp for $210M Read article
- ADMA Biologics (NASDAQ:ADMA) & Myriad Genetics (NASDAQ:MYGN) Critical Analysis Read article
- Myriad, SOPHiA partner with AstraZeneca to use prostate cancer technology Read article
- Myriad Genetics and SOPHiA GENETICS Announce New Collaboration to Advance Prostate Genomic Instability Score Technology Read article
- SOPHiA GENETICS and Myriad Genetics Announce New Collaboration to Advance Prostate Genomic Instability Score Technology Read article
Related companies
Opening the full analysis uses 1 of your 3 free tickers today.
Educational tool only — not investment advice.